Abstract

The mission of the Prostate Cancer (PR) Program is to reduce the morbidity and mortality associated with Prostate Cancer by leveraging a deep understanding of the disease at a biologic, clinical, and population level. The Program approaches this mission with transdisciplinary research that is richly collaborative and translational. Since the last competitive renewal, a strategic planning process led to the development of three new transdisciplinary themes: Theme 1: Discovery of Biologic and Molecular Drivers of Prostate Cancer Theme 2: Biomarker and Prognostic Model Development to Predict Outcomes in Men with Prostate Cancer Theme 3: Developing Therapeutic Interventions to Improve Outcomes for Men with Prostate Cancer PR Program: Key Metrics Membership (10 departments, 1 school) 37 Full 24 Associate 13 Cancer-relevant Funding (direct costs as of $13,878,515 05/31/2017) NCI $5,543,247 40% Peer-reviewed $5,289,510 38% Non-peer-reviewed $3,045,758 22% Cancer-relevant Publications (1/2012-7/2017) 616 Inter-programmatic 160 26% Intra-Programmatic 257 42% High-Impact 198 32% Accruals to Clinical Trials (2016) 923 46 Therapeutic 99 20 Other Interventional 416 12 Non-interventional 408 14

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-20
Application #
9773939
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118

  Publications

An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications